he Directors of Proteome Sciences look forward to updating shareholders on the Company’s performance, and on the outlook for 2020, at the time of announcing the 2019 full year results which are scheduled for release on 31 March 2020.
Annual General Meeting
The Annual General Meeting of the Company will take place at the offices of Allenby Capital, 5 St Helen's Place, London EC3A 6AB, at 2.30pm on 29 April 2020. Formal notice of such will be posted to shareholders with the annual report in April.
The Company received notification yesterday from Vulpes Life Sciences Fund ("Vulpes") that on 28 February 2020 it purchased 256,424 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.00p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,203,158 Ordinary Shares, equivalent to approximately 22 per cent of the issued share capital of the Company.
The Company is pleased to provide a further trading update for the financial year ended 31 December 2019.
The Company today provides a trading update for the financial year ended 31 December 2019.
Proteome Sciences plc (AIM: PRM) is pleased to announce that its services platform has continued to strengthen through the third quarter, during which a record number of 43 quotes for new business were issued.
Commenting on these results, Jeremy Haigh, Chief Executive Officer of Proteome Sciences, said:
“Performance during the first six months of 2019 was very encouraging, building on the momentum developed in the second half of 2018. Recognised revenues from our services platform were significantly ahead of the equivalent period in 2018 and, most importantly, we issued a record number of quotes for new business in the second quarter, a fundamental lead indicator of future customer engagement.
Following the announcement of TMTpro 16plex isobaric mass tags during the American Society for Mass Spectrometry (ASMS) meeting in Atlanta in June, Proteome Sciences is launching upgrades to its core proteomic services (SysQuant®, TMTcalibrator™ and Plasma Super Depletion) with increased multiplexing.
New report on growing opportunities for TMT: “Tandem Mass Tag Usage Could Benefit From New Methods, Expanded Applications” available to premium subscribers of GenomeWeb
New report on growing opportunities for TMT: “Tandem Mass Tag Usage Could Benefit From New Methods, Expanded Applications” available to premium subscribers of GenomeWeb. Link here
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 2.30 p.m. today, all resolutions were duly passed.
A copy of the presentation given by the CEO, Jeremy Haigh, at the AGM will be available on the Company’s website tomorrow. Link here to AGM slides
At the Company’s AGM being held today at 2.30 pm the Chairman, Christopher Pearce, will make the following statement:
“As indicated in our recent results, we remain optimistic about the future, with the near-term availability of higher-plex TMT® set to add significant value to this asset, and the utility of quantitative proteomics increasing in response to diagnostic advances and disruptive technologies. We are pleased to report a good first quarter, with further growth in sales and royalties from TMT® and an improving services business continuing the trend in orders and revenues established during the latter part of 2018.”